Piero Ruggenenti1, Erica Daina2, Alessia Gennarini3, Camillo Carrara1, Sara Gamba2, Marina Noris2, Nadia Rubis2, Francesco Peraro2, Flavio Gaspari2, Andrea Pasini4, Angelo Rigotti5, Renelda M Lerchner6, Domenico Santoro7, Antonio Pisani8, Alessandra Pasi9, Giuseppe Remuzzi10. 1. Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy; Unit of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy. 2. Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy. 3. Unit of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy. 4. Nephrology and Dialysis Unit, Department of Pediatrics, Azienda Ospedaliero Universitaria, Policlinico Sant'Orsola-Malpighi, Bologna, Italy. 5. Unit of Nephrology and Dialysis, Ospedale Infermi di Rimini, AUSL della Romagna, Bolzano, Italy. 6. Unit of Nephrology and Dialysis, Ospedale di Bolzano, Bolzano, Italy. 7. Unit of Nephrology and Dialysis, Policlinico "G. Martino", Messina, Italy. 8. Cattedra di Nefrologia, Università Federico II, Napoli, Italy. 9. Unit of Nephrology, Ospedale Cà Foncello, Treviso, Italy. 10. Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy; L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. Electronic address: giuseppe.remuzzi@marionegri.it.
Abstract
RATIONALE & OBJECTIVE: Primary membranoproliferative glomerulonephritis (MPGN) is a rare glomerulopathy characterized by complement dysregulation. MPGN progresses rapidly to kidney failure when it is associated with nephrotic syndrome. We assessed the effects of C5 convertase blockade in patients with MPGN and terminal complement activation. STUDY DESIGN: Prospective off-on-off-on open-label clinical trial. SETTING & PARTICIPANTS: Consenting patients with immune complex-mediated MPGN (n=6) or C3 glomerulonephritis (n=4) with sC5b-9 (serum complement membrane attack complex) plasma levels>1,000ng/mL and 24-hour proteinuria with protein excretion>3.5g identified from the Italian Registry of MPGN and followed up at the Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Bergamo, Italy) between March 4, 2014, and January 7, 2015. INTERVENTION: Anti-C5 monoclonal antibody eculizumab administered during 2 sequential 48-week treatment periods separated by one 12-week washout period. OUTCOMES: Primary outcome was change in 24-hour proteinuria (median of 3 consecutive measurements) at 24 and 48 weeks. RESULTS: Median proteinuria decreased from protein excretion of 6.03 (interquartile range [IQR], 4.8-12.4) g/d at baseline to 3.74 (IQR, 3.2-4.4) g/d at 24 weeks (P=0.01) and to 5.06 (IQR, 3.1-5.8) g/d (P=0.006) at 48 weeks of treatment, recovered toward baseline during the washout period, and did not significantly decrease thereafter. Hypoalbuminemia, dyslipidemia, and glomerular sieving function improved during the first treatment period. 3 patients achieved partial remission of nephrotic syndrome and all had undetectable C3 nephritic factors before treatment. Mean measured glomerular filtration rate was 69.7±35.2 versus 87.4±55.1 and 75.8±42.7 versus 76.6±44.1mL/min/1.73m2 at the start versus the end of the first and second treatment periods, respectively, among all 10 study participants. Unlike C3, sC5b-9 plasma levels normalized during both treatment periods and recovered toward baseline during the washout in all patients. LIMITATIONS: Single-arm design, small sample size. CONCLUSIONS: Eculizumab blunted terminal complement activation in all patients with immune complex-mediated MPGN or C3 glomerulonephritis and nephrotic syndrome, but persistently reduced proteinuria in just a subgroup. TRIAL REGISTRATION: Registered in the EU Clinical Trials Register with study no. 2013-003826-10.
RATIONALE & OBJECTIVE: Primary membranoproliferative glomerulonephritis (MPGN) is a rare glomerulopathy characterized by complement dysregulation. MPGN progresses rapidly to kidney failure when it is associated with nephrotic syndrome. We assessed the effects of C5 convertase blockade in patients with MPGN and terminal complement activation. STUDY DESIGN: Prospective off-on-off-on open-label clinical trial. SETTING & PARTICIPANTS: Consenting patients with immune complex-mediated MPGN (n=6) or C3 glomerulonephritis (n=4) with sC5b-9 (serum complement membrane attack complex) plasma levels>1,000ng/mL and 24-hour proteinuria with protein excretion>3.5g identified from the Italian Registry of MPGN and followed up at the Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Bergamo, Italy) between March 4, 2014, and January 7, 2015. INTERVENTION: Anti-C5 monoclonal antibody eculizumab administered during 2 sequential 48-week treatment periods separated by one 12-week washout period. OUTCOMES: Primary outcome was change in 24-hour proteinuria (median of 3 consecutive measurements) at 24 and 48 weeks. RESULTS: Median proteinuria decreased from protein excretion of 6.03 (interquartile range [IQR], 4.8-12.4) g/d at baseline to 3.74 (IQR, 3.2-4.4) g/d at 24 weeks (P=0.01) and to 5.06 (IQR, 3.1-5.8) g/d (P=0.006) at 48 weeks of treatment, recovered toward baseline during the washout period, and did not significantly decrease thereafter. Hypoalbuminemia, dyslipidemia, and glomerular sieving function improved during the first treatment period. 3 patients achieved partial remission of nephrotic syndrome and all had undetectable C3 nephritic factors before treatment. Mean measured glomerular filtration rate was 69.7±35.2 versus 87.4±55.1 and 75.8±42.7 versus 76.6±44.1mL/min/1.73m2 at the start versus the end of the first and second treatment periods, respectively, among all 10 study participants. Unlike C3, sC5b-9 plasma levels normalized during both treatment periods and recovered toward baseline during the washout in all patients. LIMITATIONS: Single-arm design, small sample size. CONCLUSIONS:Eculizumab blunted terminal complement activation in all patients with immune complex-mediated MPGN or C3 glomerulonephritis and nephrotic syndrome, but persistently reduced proteinuria in just a subgroup. TRIAL REGISTRATION: Registered in the EU Clinical Trials Register with study no. 2013-003826-10.
Authors: Tilman Schmidt; Sara Afonso; Luce Perie; Karin Heidenreich; Sonia Wulf; Christian F Krebs; Peter F Zipfel; Thorsten Wiech Journal: Front Immunol Date: 2022-05-27 Impact factor: 8.786
Authors: Caroline Duineveld; Eric J Steenbergen; Andrew S Bomback; Nicole C A J van de Kar; Jack F M Wetzels Journal: Pediatr Nephrol Date: 2020-05-23 Impact factor: 3.714
Authors: Fernando Caravaca-Fontán; Montserrat M Díaz-Encarnación; Laura Lucientes; Teresa Cavero; Virginia Cabello; Gema Ariceta; Luis F Quintana; Helena Marco; Xoana Barros; Natalia Ramos; Nuria Rodríguez-Mendiola; Sonia Cruz; Gema Fernández-Juárez; Adela Rodríguez; Ana Pérez de José; Cristina Rabasco; Raquel Rodado; Loreto Fernández; Vanessa Pérez Gómez; Ana I Ávila; Luis Bravo; Javier Lumbreras; Natalia Allende; Maria Dolores Sanchez de la Nieta; Eva Rodríguez; Teresa Olea; Marta Melgosa; Ana Huerta; Rosa Miquel; Carmen Mon; Gloria Fraga; Alberto de Lorenzo; Juliana Draibe; Marta Cano-Megías; Fayna González; Amir Shabaka; Maria Esperanza López-Rubio; María Ángeles Fenollosa; Luis Martín-Penagos; Iara Da Silva; Juana Alonso Titos; Santiago Rodríguez de Córdoba; Elena Goicoechea de Jorge; Manuel Praga Journal: Clin J Am Soc Nephrol Date: 2020-08-19 Impact factor: 8.237
Authors: Marloes A H M Michels; Kioa L Wijnsma; Roel A J Kurvers; Dineke Westra; Michiel F Schreuder; Joanna A E van Wijk; Antonia H M Bouts; Valentina Gracchi; Flore A P T Engels; Mandy G Keijzer-Veen; Eiske M Dorresteijn; Elena B Volokhina; Lambertus P W J van den Heuvel; Nicole C A J van de Kar Journal: Pediatr Nephrol Date: 2021-09-02 Impact factor: 3.714